Catalyst Pharmaceuticals Inc
CPRX24.350USD
-0.100-0.41%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
3.00BMarket Cap
13.59P/E TTM
More Details of Catalyst Pharmaceuticals Inc Company
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Catalyst Pharmaceuticals Inc Info
Ticker SymbolCPRX
Company nameCatalyst Pharmaceuticals Inc
IPO dateNov 08, 2006
CEODaly (Richard J)
Number of employees181
Security typeOrdinary Share
Fiscal year-endNov 08
Address355 Alhambra Circle
CityCORAL GABLES
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33134
Phone13055292522
Websitehttps://catalystpharma.com/
Ticker SymbolCPRX
IPO dateNov 08, 2006
CEODaly (Richard J)
Company Executives of Catalyst Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.15M
-3.07%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
1.08M
+1.11%
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
497.44K
+0.28%
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
381.98K
+0.37%
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
238.93K
+5.35%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
238.46K
+1.83%
Dr. Gary Ingenito, M.D., Ph.D.
Dr. Gary Ingenito, M.D., Ph.D.
Chief Medical Officer and Regulatory Officer
Chief Medical Officer and Regulatory Officer
68.87K
--
Dr. Preethi Sundaram, Ph.D.
Dr. Preethi Sundaram, Ph.D.
Chief Strategy Officer
Chief Strategy Officer
50.51K
+11.44%
Mr. Jeffrey Del Carmen
Mr. Jeffrey Del Carmen
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.51K
+140.01%
Ms. Molly Harper
Ms. Molly Harper
Lead Independent Director
Lead Independent Director
9.11K
+18.37%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.15M
-3.07%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
1.08M
+1.11%
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
497.44K
+0.28%
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
381.98K
+0.37%
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
238.93K
+5.35%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
238.46K
+1.83%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.98%
The Vanguard Group, Inc.
7.07%
State Street Investment Management (US)
5.21%
Deerfield Management Company, L.P.
4.05%
McEnany (Patrick James)
3.38%
Other
67.32%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.98%
The Vanguard Group, Inc.
7.07%
State Street Investment Management (US)
5.21%
Deerfield Management Company, L.P.
4.05%
McEnany (Patrick James)
3.38%
Other
67.32%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.17%
Investment Advisor/Hedge Fund
27.08%
Hedge Fund
11.03%
Individual Investor
6.07%
Research Firm
2.77%
Pension Fund
1.37%
Bank and Trust
0.51%
Family Office
0.14%
Sovereign Wealth Fund
0.07%
Other
6.79%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
701
106.95M
89.84%
+15.25K
2025Q3
712
106.95M
90.45%
+1.69M
2025Q2
692
104.76M
87.33%
+3.07M
2025Q1
677
101.32M
86.64%
-4.35M
2024Q4
648
100.17M
86.81%
+1.55M
2024Q3
616
97.42M
88.20%
-1.98M
2024Q2
584
98.72M
96.71%
+772.63K
2024Q1
576
98.03M
86.91%
-4.54M
2023Q4
556
86.46M
95.57%
+3.15M
2023Q3
535
83.30M
96.60%
-1.62M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
16.29M
13.31%
-124.58K
-0.76%
Jun 30, 2025
The Vanguard Group, Inc.
8.74M
7.14%
+268.10K
+3.16%
Jun 30, 2025
State Street Investment Management (US)
5.48M
4.48%
-52.05K
-0.94%
Jun 30, 2025
Deerfield Management Company, L.P.
2.88M
2.35%
-542.67K
-15.86%
Jun 30, 2025
McEnany (Patrick James)
4.28M
3.5%
-200.00K
-4.46%
Jun 09, 2025
Renaissance Technologies LLC
3.25M
2.66%
+295.20K
+9.99%
Jun 30, 2025
Fundsmith LLP
2.71M
2.21%
+557.81K
+25.93%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.87M
2.34%
+101.13K
+3.66%
Jun 30, 2025
American Century Investment Management, Inc.
1.76M
1.44%
+1.23M
+233.86%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.91M
1.56%
-279.90K
-12.80%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.37%
Invesco Biotechnology & Genome ETF
3.14%
Invesco S&P SmallCap Health Care ETF
1.5%
Janus Henderson Small Cap Growth Alpha ETF
1.46%
Invesco S&P SmallCap 600 GARP ETF
1.39%
ETC 6 Meridian Small Cap Equity ETF
1.27%
VictoryShares Small Cap Free Cash Flow ETF
1.15%
Invesco S&P SmallCap 600 Pure Growth ETF
1.1%
First Trust Small Cap US Equity Select ETF
1.07%
Cambria Value and Momentum ETF
0.97%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.37%
Invesco Biotechnology & Genome ETF
Proportion3.14%
Invesco S&P SmallCap Health Care ETF
Proportion1.5%
Janus Henderson Small Cap Growth Alpha ETF
Proportion1.46%
Invesco S&P SmallCap 600 GARP ETF
Proportion1.39%
ETC 6 Meridian Small Cap Equity ETF
Proportion1.27%
VictoryShares Small Cap Free Cash Flow ETF
Proportion1.15%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.1%
First Trust Small Cap US Equity Select ETF
Proportion1.07%
Cambria Value and Momentum ETF
Proportion0.97%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Catalyst Pharmaceuticals Inc?
The top five shareholders of Catalyst Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A. holds 16.29M shares, accounting for 13.31% of the total shares.
The Vanguard Group, Inc. holds 8.74M shares, accounting for 7.14% of the total shares.
State Street Investment Management (US) holds 5.48M shares, accounting for 4.48% of the total shares.
Deerfield Management Company, L.P. holds 2.88M shares, accounting for 2.35% of the total shares.
McEnany (Patrick James) holds 4.28M shares, accounting for 3.50% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 16.29M shares, accounting for 13.31% of the total shares.
The Vanguard Group, Inc. holds 8.74M shares, accounting for 7.14% of the total shares.
State Street Investment Management (US) holds 5.48M shares, accounting for 4.48% of the total shares.
Deerfield Management Company, L.P. holds 2.88M shares, accounting for 2.35% of the total shares.
McEnany (Patrick James) holds 4.28M shares, accounting for 3.50% of the total shares.
What are the top three shareholder types of Catalyst Pharmaceuticals Inc?
The top three shareholder types of Catalyst Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
How many institutions hold shares of Catalyst Pharmaceuticals Inc (CPRX)?
As of 2025Q4, 701 institutions hold shares of Catalyst Pharmaceuticals Inc, with a combined market value of approximately 106.95M, accounting for 89.84% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.61%.
What is the biggest source of revenue for Catalyst Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Catalyst Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
